Vedolizumab Not Associated With Increased Risk of C Diff in Patients With IBD, Study Finds; Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associ

Press/Media

Period6 Sep 2023

Media coverage

2

Media coverage

  • TitleVedolizumab Not Associated With Increased Risk of C Diff in Patients With IBD, Study Finds; Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associ
    Media name/outletConsultant Live
    Country/TerritoryUnited States
    Date6/09/23
    PersonsSaad Alshahrani
  • TitleVedolizumab Not Associated With Increased Risk of C Diff in Patients With IBD, Study Finds
    Media name/outletHCP Live
    Country/TerritoryUnited States
    Date6/09/23
    PersonsSaad Alshahrani